Short sleepers cruise by on four to six hours a night and don’t seem to suffer ill effects. Turns out they’re genetically ...

NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous ...

This study introduces an innovative pharmacological platform for treating diabetes-related cognitive and sleep disorders. The research integrates dual orexin receptor agonists (DOXA), neuropeptide ...

Orexin-2 receptor ("OX2R") partial agonist ... of mazindol and their use in treating attention deficit disorders ("ADHD") as well as sleep disorders. United States Patent No. 11,596,622: Granted ...

In 2024, net sales of LYBALVI grew 46% year-over-year, primarily driven by underlying TRx growth of 39%, with growth coming from both the schizophrenia and bipolar I disorder indications.

ZURICH and NESS ZIONA, Israel - NLS Pharmaceutics Ltd. (Nasdaq: NLSP) and Kadimastem Ltd. (TASE: KDST) announced plans for a merger, aiming to enhance diabetes treatment by combining their expertise ...

This manuscript by Tesmer and colleagues uses fiber photometry recordings, sophisticated analysis of movement, and deep learning algorithms to provide compelling evidence that activity in hypothalamic ...

Previously, a vicious circle was described for depression and sleep disorders (the dysregulation of hypocretin/orexin) (1–3 ... noted the possible correlation between the hypocretin system and mood ...

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to developing therapies for rare and complex central nervous ...

1 Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany 2 Institute of Health and Wellbeing, Federation University Australia and Victorian Heart ...